Sunshine Biopharma Inc. (SBFM) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Sunshine Biopharma Inc. (NASDAQ: SBFM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $3.33 (+7.07% 1D, market cap $2.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SBFM ranks #531 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SBFM carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 33.8%, and ROIC of -21.4%. By comparison, APVO (Aptevo Therapeutics Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M) and PRFX (PRF Technologies Ltd.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $2.6M). Among the 5-stock peer group, SBFM leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).
Per SBFM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001402328), Sunshine Biopharma Inc. generated $36.3M in revenue (+4.1% YoY), -$6.0M in net income, and -$5.5M in free cash flow against $30.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 27.3 (OVERSOLD (<32))
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While SBFM currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.16) and Max Pain ($3.50) forces dealer call-delta covering toward $487.20.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Sunshine Biopharma Inc. (SBFM) surged +7.07% to $3.33, trading at 2% of its 52-week range ($2.58 – $464). Stretched risk/reward at current multiples (-21% return on capital) under elevated 10-year interest-rate pressure.
FORT LAUDERDALE, FL / ACCESS Newswire / October 22, 2026 / (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +4.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SBFM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SBFM. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Sunshine Biopharma Inc. (SBFM) ranks #531 by composite RQD confidence (44/100, grade D) and #986 by equity capitalization ($2.5M). Within this direct 5-issuer industry benchmark cohort, SBFM leads on earnings valuation at N/A trailing P/E, while SBFM leads on capital efficiency and profitability with -21.4% ROIC and 33.8% gross margin. APVO currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with SBFM at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SBFM
ACTIVE
Sunshine Biopharma Inc. | D | 44/100 | — | 33.8% | -21.4% | +7.07% | $2.5M | Benchmark Subject |
| APVO Aptevo Therapeutics Inc. | D | 46/100 | — | — | -35.0% | +4.62% | $2.5M | /apvo-vs-sbfm → |
| PRFX PRF Technologies Ltd. | D- | 39/100 | — | -30.0% | -35.0% | -3.86% | $2.6M | /prfx-vs-sbfm → |
| HCWB HCW Biologics Inc. | E | 27/100 | — | 20.0% | -35.0% | -3.28% | $2.6M | /hcwb-vs-sbfm → |
| SILO Silo Pharma Inc. | E | 19/100 | — | 38.6% | -35.0% | -6.72% | $2.4M | /silo-vs-sbfm → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sunshine Biopharma Inc. (SBFM) reported GAAP revenue of $36.3M (+4.1% vs. FY2024 revenue of $34.9M , and +50.7% cumulative change since FY2023) , GAAP net income of -$6.0M, operating cash flow of -$5.3M, and free cash flow of -$5.5M (+61.2% YoY). On the balance sheet, SBFM closed FY2025 with $30.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $36.3M | -$6.0M | -$5.3M | -$5.5M | $30.1M | — |
| FY2024 (FY) | 2024-12-31 | $34.9M | -$5.1M | -$12.5M | -$14.2M | $30.6M | — |
| FY2023 (FY) | 2023-12-31 | $24.1M | -$4.5M | -$8.8M | -$8.8M | — | — |
As of 2026-11-01, Sunshine Biopharma Inc. (NASDAQ: SBFM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $3.33 (+7.07% 1D, market cap $2.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SBFM ranks #531 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SBFM carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 33.8%, and ROIC of -21.4%. By comparison, APVO (Aptevo Therapeutics Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M) and PRFX (PRF Technologies Ltd.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $2.6M). Among the 5-stock peer group, SBFM leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).
Per SBFM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001402328), Sunshine Biopharma Inc. generated $36.3M in revenue (+4.1% YoY), -$6.0M in net income, and -$5.5M in free cash flow against $30.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
SBFM last traded at $3.33 (+7.07% on volume of 183,387 shares), positioning the stock -76.48% below its 50-day simple moving average ($14.16) and -96.95% below its 200-day simple moving average ($109.05). Across its 52-week range of $2.58 to $464.00, SBFM sits at the 0.2% percentile with a 14-day RSI of 27.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.91 to $3.75).
Why SBFM Stock surged +7.07% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-21% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).